FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma By Ogkologos - November 6, 2025 281 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DREAMM-7 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Is AI Ready to Play a Leading Role in Colorectal Cancer... October 10, 2023 Mutational Patterns Drive Metastatic Aggressiveness of Appendiceal Adenocarcinomas December 21, 2022 Blinatumomab Improves Survival in Children with Relapsed Leukemia April 1, 2021 EMA Recommends Granting a Conditional Marketing Authorisation for Mirdametinib July 31, 2025 Load more HOT NEWS 2020 National Cancer Opinion Survey: Cancer Screening and Mental Health During... NHS staff shortages: What’s needed to build a sustainable cancer workforce? Rescue Cat Alerts Mom to Breast Cancer by “Aggressively” Cuddling Her... GD2-CART01 May Induce Sustained Antitumour Effect in a Proportion of Patients...
